Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jan 11, 2026

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL

Stephen J Nicholls¹, H Bryan Brewer, John J P Kastelein

¹Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH 44195, USA. nichols1@ccf.org

|November 18, 2011

Summary

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

International journal of radiation oncology, biology, physics·2016

Same author

Using Tomoauto: A Protocol for High-throughput Automated Cryo-electron Tomography.

Journal of visualized experiments : JoVE·2016

Same author

MiR-15a contributes abnormal immune response in myasthenia gravis by targeting CXCL10.

Clinical immunology (Orlando, Fla.)·2016

Same author

Minicells, Back in Fashion.

Journal of bacteriology·2016

Same author

A new variant of rabbit hemorrhagic disease virus G2-like strain isolated in China.

Virus research·2016

Same author

Tumour-suppressive role of PTPN13 in hepatocellular carcinoma and its clinical significance.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine·2016

This summary is machine-generated.

Evacetrapib effectively raises HDL cholesterol and lowers LDL cholesterol in patients with dyslipidemia, both as a standalone treatment and when combined with statins. Further research is needed to confirm its impact on cardiovascular outcomes.

Area of Science:

Cardiovascular Pharmacology
Lipid Metabolism Disorders

Background:

Cholesteryl ester transfer protein (CETP) inhibitors are investigated for cardioprotective effects.
Limited data exists on CETP inhibitors combined with statins.

Purpose of the Study:

To evaluate the biochemical effects, safety, and tolerability of evacetrapib.
To assess evacetrapib as monotherapy and in combination with statins in dyslipidemic patients.

Main Methods:

A 12-week randomized controlled trial involving 398 patients with dyslipidemia.
Participants received placebo, evacetrapib monotherapy (30-500 mg/d), or statin therapy with or without evacetrapib (100 mg/d).
Primary endpoints were changes in HDL-C and LDL-C levels.

Main Results:

Related Experiment Videos

Last Updated: Jan 11, 2026

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Evacetrapib monotherapy dose-dependently increased HDL-C and decreased LDL-C compared to placebo.
Combination therapy with statins significantly increased HDL-C and decreased LDL-C.
Statin-evacetrapib combination showed greater LDL-C reduction than evacetrapib monotherapy.

Conclusions:

Evacetrapib, alone or with statins, improves HDL-C and LDL-C levels in dyslipidemic patients.
The study suggests potential benefits, but cardiovascular outcome effects require further investigation.